APA (7th ed.) Citation

Parrondo, R. D., Paulus, A., Alegria, V., Liebowitz, D., Johnson, C., Clynes, R., . . . Ailawadhi, S. (2022). Plamotamab (XmAb®13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia. Leukemia & Lymphoma, 63(3), 738. https://doi.org/10.1080/10428194.2021.2005045

Chicago Style (17th ed.) Citation

Parrondo, Ricardo D., et al. "Plamotamab (XmAb®13676) for Ibrutinib- Refractory CXCR4-mutated Extramedullary Waldenström Macroglobulinemia." Leukemia & Lymphoma 63, no. 3 (2022): 738. https://doi.org/10.1080/10428194.2021.2005045.

MLA (9th ed.) Citation

Parrondo, Ricardo D., et al. "Plamotamab (XmAb®13676) for Ibrutinib- Refractory CXCR4-mutated Extramedullary Waldenström Macroglobulinemia." Leukemia & Lymphoma, vol. 63, no. 3, 2022, p. 738, https://doi.org/10.1080/10428194.2021.2005045.